In Japan, long-term business relationships are essential to business success. This presents a real challenge for international pharmaceutical and healthcare companies entering Japan.Japanese business culture places greater significance on relationships over business transactions. While in Western business, rapid business deals…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon Sues 2 Gx Makers over Latuda, Delays New 5-Year-Plan Announcement
February 15, 2018
- Teijin, SanBio Terminate License Agreement for Stroke Treatment; Development and Marketing Rights to Revert to SanBio
February 15, 2018
- Lonasen Patch Hits PIII Primary Target in Japan, Filing Planned in 1st Half of FY2018: Sumitomo Dainippon, Nitto Denko
February 15, 2018
- New Dosage Strength Approved for Enbrel Pen: Pfizer
February 14, 2018
- Adcetris Filed in Japan for Frontline Hodgkin’s Lymphoma: Takeda
February 14, 2018
- Zytiga Shows Consistent Efficacy in Japanese High-Risk mHNPC Patients
February 14, 2018
- New IITs for Oncolytic Virus to Begin for Head and Neck Cancer, Sarcoma: Oncolys
February 13, 2018
- Pricing Revamp for Off-Patent Brands “Within Our Expectation”: LTL Pharma CEO
February 13, 2018
- 2018 to See Transition to “Leap Phase” in Kyowa Kirin’s Midterm Plan: President
February 13, 2018
- Hiroshima Couple Arrested for Counterfeit Harvoni Case
February 9, 2018
- Nipro Grabs Rights to TC BioPharm’s CAR-T Therapy
February 9, 2018
- Kyowa Kirin Logs Higher Earnings on Milestones, Lower R&D Costs
February 9, 2018
- Ethical Drug Sales Up 2.1% in December on Cancer Meds, SGLT2
February 9, 2018
- Hisamitsu to Form Hong Kong Subsidiary to Step Up Salonpas, Mohrus Sales
February 9, 2018
- Otsuka Ups 2017 Profit Estimate on US Tax Reform
February 9, 2018
- Positive RA Data Out for JAK Inhibitor Peficitinib, Astellas Gears Up for Filing
February 9, 2018
- Fujifilm, Takeda Strike Deal on iPS Cell-Based Heart Therapy
February 9, 2018
- YL Biologics’ Enbrel Biosimilar Shows Equivalent Efficacy to Originator
February 8, 2018
- Daiichi Sankyo’s ADC U3-1402 Enters PI Study in US for NSCLC, Eyeing Its Multinational Study
February 8, 2018
- Torii Enjoys Earnings Rise on New HIV Drugs
February 7, 2018
ページ
The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…